What CVS’s Omnicare sale means for the retail pharmacy giant

CVS is parting ways with its troubled long-term care pharmacy subsidiary, Omnicare, eight months after it filed for bankruptcy.

The retail pharmacy giant announced in mid-May that a bankruptcy court had approved Omnicare’s sale to GenieRx, a joint partnership between private investment firm Milrose Capital and Integro Asset Management, a healthcare investment and management firm. The deal is valued around $250 million, according to court filings, and is expected to close later this year.

In September 2025, CVS announced Omnicare had filed for Chapter 11 bankruptcy after a federal judge ordered the subsidiary to pay almost $1 billion in penalties for allegedly overcharging Medicare, Medicaid, and military insurer Tricare for prescriptions.

David Azzolina, Omnicare’s president, said in a statement shared with Healthcare Brew that “supporting our customers and residents is our top priority” through the sale process and that the company is “fully committed to providing optimal care for the residents and customers we serve.”

Rowan Farber, CEO of Integro Healthcare Services, said in a press release that “GenieRx’s investment in Omnicare is a testament to the strength of their platform” and that it “share[s] a commitment to delivering reliable service, clinical expertise, and continuity of care to the patients and communities who depend on it most.”

Omnicare’s sale is the latest in a string of decisions by CVS to offload assets that aren’t performing well. In May 2025, the company announced its insurance subsidiary, Aetna, would leave the Affordable Care Act marketplace, noting its plans were underperforming due, in part, to higher-than-expected medical costs.

The company also announced last October plans to close more than a dozen of its primary care clinics, called Oak Street Health, blaming high medical costs and changes to the Centers for Medicare and Medicaid’s risk adjustment model.

“There is a focus on improving margins and exiting businesses that are holding them back from doing so under the new CVS management team,” Julie Utterback, senior equity analyst at investment research firm Morningstar, told Healthcare Brew.

Omnicare’s ‘downfall.’ CVS bought Omnicare in 2015 for $12.7 billion, a far bigger number than the $250 million it’s selling for now.

Omnicare didn’t perform well for years before filing for bankruptcy, and CVS deemed it a non-strategic asset in 2022, meaning it wasn’t essential to the company’s business, Utterback said. In its bankruptcy filing, Omnicare listed assets between $100 million to $500 million and liabilities of $1 billion to $10 billion, we previously reported.

“Operationally, Omnicare faced several industrywide headwinds like reimbursement and cost pressures for these senior living facility-related operations,” Utterback said via email. That, along with the nearly $1 billion penalty payment, “led to its downfall,” Utterback added.

But Utterback doesn’t anticipate Omnicare’s sale to have a material effect on CVS’s profits.

CVS’s overall revenue increased to $100.4 billion in Q1 2026, compared to $94.6 billion in Q1 2025, largely driven by improvements in its Aetna insurance business, Brian Newman, CVS’s CFO, told CNBC. The day after the Omnicare sale announcement, CVS shares closed at $97.15, an 11.2% increase over the week prior.

“For CVS and the managed care industry in general, rising medical insurance margins are really dominating the investment story right now,” Utterback said.

Omnicare also represents a small percentage of CVS’s overall business, Rohan Kulkarni, executive research leader for business consultancy HFS Research, told Healthcare Brew in September.

Zooming out. Beyond divesting assets, CVS has recently taken steps to boost the company by getting into the AI business.

“We believe the future of best-in-class healthcare companies will be powered by technology and AI,” David Joyner, CVS’s board chair and CEO, said in the company’s Q1 2026 earnings call on May 6. “AI has been deployed across CVS Health for years to improve our operations and to drive efficiencies. But what we are most excited about and believe will have the biggest impact is AI’s ability to improve consumer experiences, engagement, and outcomes.”

In March, the company announced a partnership with Google Cloud to create a consumer health agentic AI platform that falls under a new health tech services subsidiary, Health100. And the company is experimenting with digital twins to conduct research on its products and services, IT Brew reported.